In Iran, maldistribution of specialists across provinces is evident and represents a serious challenge, mirroring global ...

The LimiTEC trial explored teclistamab discontinuation in multiple myeloma, showing comparable outcomes to continuous therapy with a median PFS of 19.9 months. Fixed-duration therapy may reduce ...

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...

This was a study led by Dr. Pallawi Torka from Memorial Sloan Kettering that we participated in, where they performed as a ...

UNIONDALE, NY / ACCESS Newswire / December 8, 2025 / Marquis Who’s Who, the trusted biographical authority documenting ...

BGB-11417-202 ( NCT05479994) is an open-label, phase 2, and a potential registrational study evaluating the efficacy and safety of sonrotoclax in 100 heavily pretreated patients with R/R CLL/SLL. At a ...

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) induced a higher response rate in ...

Objectives We hypothesise that women with type 2 diabetes and hypertension are less likely than comparable men to receive renin–angiotensin system (RAS)-inhibiting antihypertensive treatment, ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemogl ...

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over ...

The word 'retarded' was once an accepted medical term before it became an insult, was gradually phased out, and has now been revived by Musk and Trump ...